R&D Focus: New report shows nearly 600 medicines in development for pediatric patients
By Andrew Powaleny | February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...
Read More
Across the country, the biopharmaceutical sector supports millions of jobs in its pursuit to discover ground-breaking treatments and cures for patients around the world.
Read More
Trump administration must defend and protect U.S. innovation
By Priscilla VanderVeer | February 6, 2020
PhRMA recently submitted comments to the Office of the United States Trade Representative (USTR)’s Special 301 Report, calling on the Trump administration to defend American biopharmaceutical...
Read More
Working together to combat coronavirus
By Richard Moscicki, M.D. | February 6, 2020
The World Health Organization (WHO) recently declared the outbreak of 2019-nCoV, a novel strain of coronavirus that originated in Wuhan, China, a global health emergency. In the last three weeks,...
Read More
Three reasons the Administration should abandon its International Pricing Index proposal
By Nicole Longo | January 31, 2020
According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American...
Read More
Drug importation: An old idea that is still a bad idea
By Nicole Longo | January 28, 2020
2020 may have kicked off a new decade, but policymakers are stuck in the past, focusing on old, dangerous ideas like drug importation. For all the same reasons we’ve discussed before, drug...
Read More
Cancer medicines cost twice as much at hospitals, study finds
By Katie Koziara | January 21, 2020
Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research...
Read More
ICYMI: 2019 brings innovative medicines to patients
By Andrew Powaleny | January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 56 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...
Read More
New GAO report: Some hospitals participating in 340B may not be eligible for the program
By Nicole Longo | January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability...
Read More
Nearly 50% of brand medicine spending goes to the supply chain and others
By Holly Campbell | January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
